1. Pneumocystis jirovecii Pneumonia in a Patient with Breast Cancer Receiving Neoadjuvant Dose-dense Chemotherapy.
- Author
-
Watanabe H, Kitahara Y, Murakami Y, Nihashi F, Matsushima S, Eifuku T, Uto T, Sato J, Imokawa S, and Suda T
- Subjects
- Adult, Female, Humans, Neoadjuvant Therapy adverse effects, Pneumocystis carinii isolation & purification, Pneumonia, Pneumocystis diagnosis, Pneumonia, Pneumocystis physiopathology, Treatment Outcome, Adrenal Cortex Hormones therapeutic use, Anti-Bacterial Agents therapeutic use, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Pneumonia, Pneumocystis chemically induced, Pneumonia, Pneumocystis drug therapy
- Abstract
We herein report a 38-year-old woman with breast cancer who developed Pneumocystis jirovecii pneumonia (PCP) during neoadjuvant dose-dense chemotherapy combined with dexamethasone as antiemetic therapy. Chest computed tomography showed bilateral ground-glass opacities and consolidation. The serum β-D-glucan levels were elevated, and P. jirovecii DNA was detected from the bronchoalveolar lavage fluid by polymerase chain reaction. Her clinical findings improved with trimethoprim/sulfamethoxazole and adjunctive steroid therapy. Clinicians must be mindful of the manifestations of PCP in non-human immunodeficiency virus (HIV)-infected immunocompromised patients and include the possibility of PCP in the differential diagnosis when confronted with breast cancer on dose-dense chemotherapy showing diffuse lung disease.
- Published
- 2020
- Full Text
- View/download PDF